Application of SLC12A3 and/or SLC12A9 as detection index for treatment and prognosis of uveal melanoma
Patent Information
- Authority / Receiving Office
- CN ยท China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV
- Publication Date
- 2022-05-13
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biomedicine, and specifically relates to the application of SLC12A3 and / or SLC12A9 as indicators for the treatment and prognosis of uveal melanoma. Background technique
[0002] Uveal melanoma (Uveal Melanoma, UVM) is the most common primary malignant tumor in the adult eye. The age of onset is mostly in people over 50-60 years old, and male patients are slightly more common. The incidence rate of uveal melanoma abroad is 0.02%. In China, uveal melanoma is the second most common intraocular malignant tumor. Uveal melanoma can occur anywhere in the uvea, but the choroid is the most common. It is usually unilateral, but rare in both eyes. Uveal melanoma cells can metastasize to distant places along with the blood line in the early stage, even before the primary ocular tumor is discovered, the distant metastasis has already begun. The metastases of uveal melanoma are mainly through the blood, and the most common me...